Prostate Cell News Volume 6.10 | Mar 20 2015

The Endogenous Cell-Fate Factor Dachshund Restrains Prostate Epithelial Cell Migration via Repression of Cytokine Secretion via a CXCL Signaling Module
Scientists showed IL-8 and IL-6 secretion was altered ~1000 fold by endogenous Dach1. Endogenous Dach1 is shown to serve as a key endogenous restraint to prostate epithelial cell growth and restrains migration via CXCL signaling. [Cancer Res] Abstract

CCAAT/Enhancer Binding Protein β Controls Androgen-Deprivation-Induced Senescence in Prostate Cancer Cells
Scientists found that CCAAT/enhancer binding protein (C/EBPβ) expression is negatively regulated by androgen receptor activity and that treatment of androgen-sensitive cell lines with anti-androgens increases C/EBPβ mRNA and protein levels. [Oncogene] Abstract

Unravelling “Off-Target” Effects of Redox-Active Polymers and Polymer Multilayered Capsules in Prostate Cancer Cells
Researchers investigated the occurrence of off-target effects in prostate cancer cells following exposure to redox-active polymer and thin multilayer capsules with different chemical properties. [Nanoscale] Abstract

TGFβ-Induced Phosphorylation of Par6 Promotes Migration and Invasion in Prostate Cancer Cells
Scientists investigated the importance of phosphorylated partition-defective 6 (Par6) in prostate cancer. Transforming growth factor β (TGFβ) induced Par6 phosphorylation on Ser345 and its recruitment to the leading edge of the membrane ruffle in migrating prostate cancer cells, where it colocalized with atypical protein kinase Cζ. [Br J Cancer] Abstract

Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-α Blocker in Prostate Cancer
Human prostate cancer cell line PC3M and a nude mouse model were used to test efficacy of nano-targeted and nano-encapsulated toremifene versus free toremifene on the growth and differentiation of tumor cells. [Pharm Res] Abstract

Paradoxical and Contradictory Effects of Imatinib in Two Cell Line Models of Hormone-Refractory Prostate Cancer
Two cell line models of hormone-refractory prostate cancer (DU145 and PC3) were exposed to 20 μM of imatinib for 6-72 hours. Imatinib significantly decreased the viability of DU145 cells but paradoxically augmented the viability of PC3 cells. [Prostate] Abstract

The Role of Tumor Suppressor Gene SOX11 in Prostate Cancer
Scientists investigated the role of SOX11 in prostate cancer and its expression pattern and clinical significance. SOX11 overexpression cell model was used to examine the role of SOX11 in cell growth and metastasis in vitro. [Tumor Biol] Abstract

CLINICAL RESEARCH

Prostate Hypofractionated Radiation Therapy with Injection of Hyaluronic Acid: Acute Toxicities in a Phase II Study
In a multicenter Phase II trial, hypofractionated irradiation was combined with an injection of hyaluronic acid to preserve the rectal wall. Tolerance of the injection and acute toxicity rates were reported. [Int J Radiat Oncol Biol Phys] Abstract

Effect of Finasteride on Serum Androstenedione and Risk of Prostate Cancer within the Prostate Cancer Prevention Trial: Differential Effect on High- and Low-Grade Disease
Scientists evaluated the effect of finasteride on serum androst-4-ene-3,17-dione (androstenedione) and its association with prostate cancer risk among subjects who participated in the Prostate Cancer Prevention Trial. [Urology] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Two Penn Medicine Gene Therapy Researchers Receive Pennsylvania Bio Awards
Two researchers from the Perelman School of Medicine at the University of Pennsylvania will be honored for their contributions for the burgeoning field of gene therapy by Pennsylvania Bio. [Perelman School of Medicine at the University of Pennsylvania] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Postdoctoral Fellow – Cancer Biology (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Position – Stem Cell Biology/Cancer Biology (Oregon Health and Science University)

Postdoctoral Research Associate – Prostate Cancer (University of Sydney)

Director – Vector Production (Sangamo BioSciences, Inc.)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Postdoctoral Research – Scientist Metabolic Adaptation in Treatment Resistant Prostate Cancer (Cancer Research UK Beatson Institute in Glasgow)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Researcher – Prostate Cancer (University of Pennsylvania)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.